SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

NASDAQ: AMRX · USD
Healthcare · Drug Manufacturers - Specialty & Generic
$21.12-$0.27 (-1.26%)
 
Market cap
$7.36B
Insider Score
Analyst consensus
Website
Market Cap$7.36B+83.4%
Revenue (ttm)$3.20B
Net Income$133.30M
EPS$0.40
Shares Out348.41M
PE Ratio52.80
Forward PE17.13
Dividendn/a
Ex-Dividend Daten/a
Volume1,672,746
Open$21.25
Previous Close$21.39
Day's Range$21.07 - $21.70
52-Week Range$11.71 - $22.13
Beta1.21
Analystsnone
Price Target$24.29(+14.99%)
Earnings DateNov 3, 2026

About AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Address
400 Crossing Boulevard, Bridgewater, NJ, 08807, United States
Market Cap
7.36 billion
Employees
8,700
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$7.67M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $20.20 (-7.7%)

3 firms rating AMRX in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-1.26%
5 Days
-1.22%
1 Month
+3.13%
6 Months
+70.05%
1 Year
+83.41%

$AMRX stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of AMRX by members of U.S. Congress

Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KMay 29, 2019
Gilbert CisnerosHouse / DSale$1.00K – $15.00KMay 29, 2019
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KMay 28, 2019
Josh GottheimerHouse / DSale$1.00K – $15.00KMay 24, 2019

Recently reported changes in AMRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AMRX's directors and management

Net Shares Purchased by Insiders−500k−250k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AMRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AMRX Revenue by Segment

$862.68MTotal
Affordable Medicines$547.11M63.42%
AvKARE$165.31M19.16%
Specialty$150.26M17.42%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AMRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AMRX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from AMRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
55
News & Sentiment
20% of score
75

News check: Amneal secured European regulatory approval for Adcomfo biosimilar, a concrete positive business achievement signaling market expansion.

Recent Insider Activity

Buys
0
Sells
5
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BCUSBancreek U.S. Large Cap ETF4.43%
PJPInvesco Pharmaceuticals ETF3.65%
ASCEAllspring SMID Core ETF3.28%
CSMDCongress SMID Growth ETF2.79%
XPHState Street SPDR S&P Pharmaceuticals ETF2.51%
BCGSBancreek Global Select ETF2.23%
PSCHInvesco S&P SmallCap Health Care ETF2.11%
SRHQSRH U.S. Quality GARP ETF1.84%
DWASInvesco Dorsey Wright SmallCap Momentum ETF1.77%
XSMOInvesco S&P SmallCap Momentum ETF1.75%
PTHInvesco Dorsey Wright Healthcare Momentum ETF1.39%
RSMCRockefeller U.S. Small-Mid Cap ETF1.32%

Weight is the stock’s share of each fund’s holdings.